RNF213 and multiminicore myopathy: Furthermore, inhibition of YAP/TAZ reversed the RNF213 knockdown-induced angiogenesis [100], suggesting that the discovery of a YAP/TAZ inhibitor might represent a therapeutic target for MMD patients with RNF213 loss-of-function mutations.